Sal, you & I must be on the same page today. I also would have liked more of an emphasis on Merck than UC San Francisco in the headline. Like I posted earlier, I'm very curious to see how the market responds. This IS very good news...I just hope market wasn't expecting a partnership for the Phase 2B.
Sal it's still early, news sometimes doesn't post until right before the trading day starts. It shows that under Td ameritrade it has the same headline for MRK as oncs posted at the same time. As for needing to raise more cash, I don't think it will be until the second half ir end of 2015. This trial is basically free. It is investigator sponsored and we don't have to pay for the drug which is around 100k a person I believe, so overall a very big positive!
Yeah I got an uh oh feeling reading the headline.Then I got excited again.Then confused if it was the Phase IIB.Then excited that we are in this ground breaking company
It is good news, but not even in the top 2 best case scenarios. Merck is dipping their toe in the water instead of jumping in. Which is better than nothing but with Dr. Pierce on staff a little more support would have been nice. Also, ONCS does not have the money to run this trial with no extra cash and a trial for a new indication. They have shown before that they like to keep at least 12 months of operating cash on hand, so I expect to see the other 2/3 of the s-3 used in the near future.
News 
Market Data 
Discover 
